表紙
市場調査レポート

癌免疫刺激剤市場・パイプライン考察 2020年

Cancer Immunomodulators Market & Pipeline Insight 2020

発行 KuicK Research 商品コード 332749
出版日 ページ情報 英文 1000 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
癌免疫刺激剤市場・パイプライン考察 2020年 Cancer Immunomodulators Market & Pipeline Insight 2020
出版日: 2015年06月16日 ページ情報: 英文 1000 Pages
概要

当レポートでは、世界の癌免疫刺激剤市場について調査し、癌免疫刺激剤の必要性、機序、および臨床パイプラインなどを分析しており、上市済み癌免疫刺激剤300製品以上の臨床考察、および特許分析などをまとめ、お届けいたします。

第1章 癌免疫刺激剤のイントロダクション

第2章 癌免疫刺激剤の機序

第3章 癌治療における免疫刺激剤の必要性

第4章 世界の癌免疫刺激剤市場概要

  • 現在の市況
  • 癌免疫刺激剤の臨床パイプライン分析

第5章 癌免疫刺激剤市場の好ましいパラメーター

  • 研究開発
  • 癌発症率の上昇
  • 組み換えDNA技術の進歩
  • 新たな経路の特定
  • より良い治療に対する需要

第6章 癌免疫刺激剤市場の課題

第7章 癌免疫刺激剤市場の将来展望

第8章 癌免疫刺激剤の臨床パイプライン:企業・適応症・位相別

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第1相
  • 第1/2相
  • 第2相
  • 第2/3相
  • 第3相
  • 登録前
  • 登録済み

第9章 上市済み癌免疫刺激剤の臨床考察

第10章 競合情勢

  • 3M Pharmaceuticals
  • AbGenomics Corporation
  • Advaxis
  • Amgen
  • ANI Pharmaceuticals
  • Argos Therapeutics
  • AVAX Technologies
  • Baxter International
  • Biosidus
  • Biovest International
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Curadev
  • GlaxoSmithKline
  • Gradalis
  • Incyte
  • Intas Biopharmaceuticals
  • iTeos Therapeutics
  • キョーリン製薬
  • Liponova
  • MedImmune
  • Merck
  • Mologen
  • NewLink Genetics Corporation
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Pfizer
  • Reliance Life Sciences
  • Roche
  • Sanofi
  • 東レ
  • Vaccinogen

図表リスト

目次

Immune system has developed myriad of techniques for preventing progression and proliferation of infectious diseases in the body. Different immunocytes vary in qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of immunomodulators. They could be natural occurring or synthetically derived molecule used for modulating activities of immune system. Immunomodulators have ability to augment or reduce immune reactions depending upon nature of ailment. In their presence, immune system produces those molecules which increase the rate of reaction and increases immunity. On the other hand, these molecules may reduce the effect of immune system in order to alleviate the patients' medical condition.

Investigators have been able to identify their clinical applicability in various diseases due to which various immunomodulator based products are entering in global market. They are continuously changing due to which they may be tweaked according to medical necessity. Owing to multiple effects on immune system, sometimes they may be observed in overlapping drug categories. Immunomodulators present in body may undergo biochemical and biophysical changes and become overactive to target own components. This case has been widely observed in autoimmune diseases where multiple issues appear without any apparent reasons. On the other hand, effective defense against removal of cancerous cells is lost due to which pharmacological preparation has to be administered. Immunomodulators are widely used in these and other categories as they proved to have superior pharmacological efficacy along with minimum adverse effects.

Immunomodulators can bring changes in immune system due to which changes in immunochemistry are observed and they could be customized to alter programming of immune system. As a result, pharmacological benefits of immunomodulators are being explored by investigators in clinical trials. Their oncological applications are being studied and various drug candidates are at different stages of clinical trials which would be commercialized in coming years. New modalities are also being discovered by investigators to increase the potency, long-term cancer remission and administration in various cancer indications. In this way, cancer immunomodulators are expected to offer better medical care to cancer patients. Few immunomodulators drugs for various cancer indications have been introduced in market and they are also expected to increase number in coming years.

Demand for novel immunomodulators having higher pharmacological benefits is escalating rapidly across the globe. Pharmaceutical companies have recognized their marketing potential of due to which higher investments are being made in research and development category. They are highly compatible in nature and easily customized due to which they could be designed according to the necessities of drug development program. Moreover, their clinical pipeline is expected to become strong due to increased rate of innovations. In coming years, new immunomodulators would be available in market that would be able to fulfill the high unmet medical demand. Increasing cancer incidences has created burgeoning pressure on pharmaceutical companies to introduce them promptly in global market. Their development may take time which is expected to be solved by technological advancements and increased knowledge about their mechanisms.

“Cancer Immunomodulators Market & Pipeline Insight 2020” Report Highlights:

  • Introduction & Need of Cancer Immunomodulators
  • Cancer Immunomodulators Mechanism
  • Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
  • Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
  • Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
  • Marketed Cancer Immunomodulators: 47
  • Cancer Immunomodulators Drug Patent Analysis

Table of Contents

1. Introduction to Cancer Immunomodulators

2. Cancer Immunomodulators Mechanism

3. Need for Immunomodulators in Cancer Therpay

4. Global Cancer Immunomodulators Market Overview

  • 4.1. Current Market Scenario
  • 4.2. Cancer Immunomodulators Clinical Pipeline Analysis

5. Cancer Immunomodulators Market Favorable Parameters

  • 5.1. Research & Development
  • 5.2. Escalating Cancer Incidences
  • 5.3. Advances in Recombinant DNA Technology
  • 5.4. Identification of New Pathways
  • 5.5. Demand for Better Therapeutics

6. Cancer Immunomodulators Market Challenges

7. Cancer Immunomodulators Market Future Outlook

8. Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase

  • 8.1. Unknown
  • 8.2. Research
  • 8.3. Preclinical
  • 8.4. Clinical
  • 8.5. Phase-I
  • 8.6. Phase-I/II
  • 8.7. Phase-II
  • 8.8. Phase-II/III
  • 8.9. Phase-III
  • 8.10. Preregistration
  • 8.11. Registered

9. Marketed Cancer Immunomodulators Clincial Insight

10. Competitive Landscape

  • 10.1. 3M Pharmaceuticals
  • 10.2. AbGenomics Corporation
  • 10.3. Advaxis
  • 10.4. Amgen
  • 10.5. ANI Pharmaceuticals
  • 10.6. Argos Therapeutics
  • 10.7. AVAX Technologies
  • 10.8. Baxter International
  • 10.9. Biosidus
  • 10.10. Biovest International
  • 10.11. Bristol-Myers Squibb
  • 10.12. Celgene Corporation
  • 10.13. Curadev
  • 10.14. GlaxoSmithKline
  • 10.15. Gradalis
  • 10.16. Incyte
  • 10.17. Intas Biopharmaceuticals
  • 10.18. iTeos Therapeutics
  • 10.19. Kyorin Pharmaceutical
  • 10.20. Liponova
  • 10.21. MedImmune
  • 10.22. Merck
  • 10.23. Mologen
  • 10.24. NewLink Genetics Corporation
  • 10.25. Northwest Biotherapeutics
  • 10.26. Novartis
  • 10.27. Peregrine Pharmaceuticals
  • 10.28. Pfizer
  • 10.29. Reliance Life Sciences
  • 10.30. Roche
  • 10.31. Sanofi
  • 10.32. Toray
  • 10.33. Vaccinogen

List of Figures

  • Figure 1-1: Functions of Immunomodulators
  • Figure 1-2: Benefits of Immunomodulators
  • Figure 1-3:Limitations of Immunomodulators
  • Figure 2-1: Mechanism of Thalidomide
  • Figure 2-2: Mechanism of Lenalidomide In Vivo
  • Figure 2-3: Mechanism of Lenalidomide In Vitro
  • Figure 2-4: Mechanism of Pomalidomide
  • Figure 2-5: Mechanism of IDO Inhibitor
  • Figure 2-6:Mechanism of TDO Inhibitor
  • Figure 2-7: Mechanism of dSLIM immunomodulator
  • Figure 4-1: Global Immunomodulators Market (US$ Billion), 2014-2020
  • Figure 4-3: Cancer Immunomodulators Pipeline by Phase (%), 2015
  • Figure 4-4: Cancer Immunomodulators Pipeline by Phase (Number), 2015
  • Figure 5-1: Cancer Immunomodulators Market Favorable Parameters
  • Figure 5-2: Cancer Immunomodulators Market Challenges
  • Figure 9-1: AbGenomics-Clinical Pipeline
  • Figure 9-2: Argos Therapeutics Clinical Pipeline
  • Figure 9-3: Gradalis Clinical Pipeline
Back to Top